Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMASCIS-01: Allogeneic MSCs in Acute Ischemic Stroke
NCT01678534Phase 2Completed
- Sponsor
- Hospital La Paz Institute for Health Research
- Start
- Sep 2014
- Primary completion
- Dec 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CSCC_ASC in ischemic stroke (2 arms), sponsored by Hospital La Paz Institute for Health Research. Primary endpoint: Number of participants with Adverse events, complications at 24 months. Started Sep 2014; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01678534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01678534.